Brief: Bristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59
30/07/2026 11:59
BRIEF-Bristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59 July 30 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS OUTLOOK FY ADJUSTED EPS $6.75 TO $7 VERSUS IBES ESTIMATE $6.34
BRISTOL MYERS Q2 REVENUE $12.97 BILLION VERSUS IBES ESTIMATE $11.75 BILLION
BRISTOL MYERS OUTLOOK FY ELIQUIS REVENUE GROWTH 20%-25% VERSUS PRIOR FORECAST OF 10%-15%
BRISTOL MYERS Q2 ADJUSTED EPS $2.04 VERSUS IBES ESTIMATE $1.59
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma